A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design
Background The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab w...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 9; no. 1; p. 56 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
14.10.2008
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1745-6215 1745-6215 |
| DOI | 10.1186/1745-6215-9-56 |
Cover
| Abstract | Background
The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data.
Methods and design
The Avastin
®
(bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change.
Discussion
The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy.
Trial registration
Current controlled trials ISRCTN83325075 |
|---|---|
| AbstractList | BackgroundThe management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data.Methods and designThe Avastin® (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change.DiscussionThe ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy.Trial registrationCurrent controlled trials ISRCTN83325075 The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data.BACKGROUNDThe management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data.The Avastin(R) (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining >/= 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change.METHODS AND DESIGNThe Avastin(R) (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining >/= 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change.The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy.DISCUSSIONThe ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy.Current controlled trials ISRCTN83325075.TRIAL REGISTRATIONCurrent controlled trials ISRCTN83325075. BACKGROUND: The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data. METHODS AND DESIGN: The Avastin® (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change. DISCUSSION: The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy. TRIAL REGISTRATION: Current controlled trials ISRCTN83325075 Abstract Background The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data. Methods and design The Avastin® (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change. Discussion The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy. Trial registration Current controlled trials ISRCTN83325075 The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data. The Avastin(R) (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining >/= 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change. The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy. Current controlled trials ISRCTN83325075. Background The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of bevacizumab for nAMD has come from interventional case series and this clinical trial was initiated because of the increasing and widespread use of this agent in the treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy data. Methods and design The Avastin ® (bevacizumab) for choroidal neovascularisation (ABC) trial is a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy, intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control arm as it had not been licensed for use at the start of recruitment for this trial. The primary outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary outcomes include the proportion of patients with stable vision and mean visual acuity change. Discussion The ABC Trial is the first double-masked randomised control trial to investigate the efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited in November 2007 and results should be available in early 2009. Important design issues for this clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous therapy. Trial registration Current controlled trials ISRCTN83325075 |
| ArticleNumber | 56 |
| Audience | Academic |
| Author | Bunce, Catey Patel, Praveen J Tufail, Adnan |
| AuthorAffiliation | 1 Moorfields Eye Hospital, 162 City Road, London, UK |
| AuthorAffiliation_xml | – name: 1 Moorfields Eye Hospital, 162 City Road, London, UK |
| Author_xml | – sequence: 1 givenname: Praveen J surname: Patel fullname: Patel, Praveen J organization: Moorfields Eye Hospital – sequence: 2 givenname: Catey surname: Bunce fullname: Bunce, Catey organization: Moorfields Eye Hospital – sequence: 3 givenname: Adnan surname: Tufail fullname: Tufail, Adnan email: adnan.tufail@moorfields.nhs.uk organization: Moorfields Eye Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18854025$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1k9tu1DAQhgMqgh645RJZ4gKQSBvnHC6QlorDSpW4AW6tiT3OeknixU4WLQ_FQ_BkTHZL2y1UkRJn_P_f2OPxUXDQ2x6D4AmPTjkv8zNepFmYxzwLqzDL7weHV4GDG-NHwZH3yyhKkypJHwaPeFlmaRRnh_dOZsxBr2xnPKpXTNmxbjHswH9DxVYL8Mjm8_nZ_Cvzw6g2zGo2LJCh1kaC3DDyMg8ah-3UbA1-MP3vX-zFW1yDND_HDuqXzPSDg7UZHEJLP0uUg7G9Z9J2K3CUabDEJxY4NfEdrDakY36sJ61nP8ywYHJhnTWKED1ayiTHFpzxMLGYR2kn_2ZiQYOhwxYGQnew1TGFDfZEntSvmWxNTzto2eAMvRV60_QnwQMNrcfHl9_j4Mv7d5_PP4YXnz7Mz2cXYZ2n5RBWVaoxRZ0kSmcxcKniRBelhjTmKHVdcx0p1BnElVJVHsc84lrqMudRxnWpk-NgvuMqC0uxcqajdQsLRmwD1jUC3GBki4LzAoqiijlgkmJd1hXUmNZlUYMsZVET682OtRrrDpXEqdTtHnR_pjcL0di1iLMij9KKALMdoDb2DsD-DB2amDpLTJ0lKpHlxHh-uQhnv4_oB0H9JLFtgU5q9KJIUl5WWcJJ-eyWcmlH11O1RVxUaRVnURVfqxqgGpheW8osJ6aYUe9GUZQQ7Tg4_Y-KHoWdoW5AbSi-Z3h6s1ZXe_x7HUiQ7gTSWe8daiHNsO0YIptW8EhMt-7f7Z_esl2R7zKc7QyehH2D7roKdzj-ACqiREA |
| CitedBy_id | crossref_primary_10_1586_17512433_2015_1075879 crossref_primary_10_1136_bjophthalmol_2021_319383 crossref_primary_10_3109_02713683_2011_611609 crossref_primary_10_1016_j_xops_2024_100524 crossref_primary_10_1097_IAE_0b013e3181a94f01 crossref_primary_10_1007_s00417_013_2421_5 crossref_primary_10_1016_j_preteyeres_2008_11_004 crossref_primary_10_1159_000533481 crossref_primary_10_1007_s00717_009_0346_5 crossref_primary_10_1111_cts_12974 crossref_primary_10_2217_pgs_12_77 crossref_primary_10_1155_2012_483034 crossref_primary_10_1155_2011_752543 crossref_primary_10_1111_j_1755_3768_2009_01659_x crossref_primary_10_1179_his_2010_33_1_15 crossref_primary_10_1002_14651858_CD005139_pub3 crossref_primary_10_1002_14651858_CD005139_pub4 crossref_primary_10_1002_pds_1646 crossref_primary_10_1016_j_survophthal_2012_01_006 crossref_primary_10_1111_aos_14574 |
| Cites_doi | 10.1097/00006982-200604000-00001 10.1167/iovs.07-1132 10.1001/archopht.117.10.1329 10.1056/NEJMoa042760 10.1167/iovs.06-0433 10.1136/bmj.308.6921.81 10.1016/j.ophtha.2005.11.019 10.1056/NEJMoa032691 10.1016/S0002-9394(01)00967-9 10.1016/S0161-6420(99)90255-5 10.1001/archopht.122.7.1019 10.1056/NEJMoa054481 10.1056/NEJMoa062655 |
| ContentType | Journal Article |
| Contributor | Segun-Odumosu, Ola Ikeji, F Henderson, L Waller, K Majid, M Hykin, P Dowler, J Bailey, C Bunce, C Richardson, M Tufail, A da Cruz, L Patel, P J Egan, C Mohamed, Q Johnston, R Gregor, Z |
| Contributor_xml | – sequence: 1 givenname: A surname: Tufail fullname: Tufail, A – sequence: 2 givenname: L surname: Henderson fullname: Henderson, L – sequence: 3 givenname: Ola surname: Segun-Odumosu fullname: Segun-Odumosu, Ola – sequence: 4 givenname: C surname: Bunce fullname: Bunce, C – sequence: 5 givenname: P J surname: Patel fullname: Patel, P J – sequence: 6 givenname: L surname: da Cruz fullname: da Cruz, L – sequence: 7 givenname: J surname: Dowler fullname: Dowler, J – sequence: 8 givenname: C surname: Egan fullname: Egan, C – sequence: 9 givenname: Z surname: Gregor fullname: Gregor, Z – sequence: 10 givenname: P surname: Hykin fullname: Hykin, P – sequence: 11 givenname: Q surname: Mohamed fullname: Mohamed, Q – sequence: 12 givenname: R surname: Johnston fullname: Johnston, R – sequence: 13 givenname: M surname: Majid fullname: Majid, M – sequence: 14 givenname: C surname: Bailey fullname: Bailey, C – sequence: 15 givenname: F surname: Ikeji fullname: Ikeji, F – sequence: 16 givenname: M surname: Richardson fullname: Richardson, M – sequence: 17 givenname: K surname: Waller fullname: Waller, K |
| Copyright | Patel et al; licensee BioMed Central Ltd. 2008 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. COPYRIGHT 2008 BioMed Central Ltd. Patel et al; licensee BioMed Central Ltd. 2008. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This work is published under http://creativecommons.org/licenses/by/2/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2008 Patel et al; licensee BioMed Central Ltd. 2008 Patel et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Patel et al; licensee BioMed Central Ltd. 2008 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: COPYRIGHT 2008 BioMed Central Ltd. – notice: Patel et al; licensee BioMed Central Ltd. 2008. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This work is published under http://creativecommons.org/licenses/by/2/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2008 Patel et al; licensee BioMed Central Ltd. 2008 Patel et al; licensee BioMed Central Ltd. |
| CorporateAuthor | the ABC Trial Investigators ABC Trial Investigators |
| CorporateAuthor_xml | – name: the ABC Trial Investigators – name: ABC Trial Investigators |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/1745-6215-9-56 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals (WRLC) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 56 |
| ExternalDocumentID | oai_doaj_org_article_117a77921ae34eb8b9abe4b87bac8c7b PMC2576049 oai_biomedcentral_com_1745_6215_9_56 A188000395 18854025 10_1186_1745_6215_9_56 |
| Genre | Journal Article |
| GeographicLocations | United Kingdom Europe |
| GeographicLocations_xml | – name: United Kingdom – name: Europe |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2VQ 2WC 4.4 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHSBF AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C1A C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SMD SOJ TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION NPM PMFND 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 -5E -5G -A0 -BR ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM |
| ID | FETCH-LOGICAL-b648t-994fe4ef33df52a1cd23f78fa421ecfbb1f0def5a29dd9622101fcf861051f8f3 |
| IEDL.DBID | M48 |
| ISSN | 1745-6215 |
| IngestDate | Wed Aug 27 01:31:53 EDT 2025 Thu Aug 21 14:34:54 EDT 2025 Wed May 22 07:11:18 EDT 2024 Thu Sep 04 22:30:35 EDT 2025 Fri Jul 25 22:05:25 EDT 2025 Tue Jun 17 22:20:26 EDT 2025 Tue Jun 10 21:15:19 EDT 2025 Mon Jul 21 06:06:13 EDT 2025 Tue Jul 01 04:00:35 EDT 2025 Thu Apr 24 23:13:55 EDT 2025 Sat Sep 06 07:26:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Well Correct Visual Acuity Optical Coherence Tomography Visual Acuity Ranibizumab Bevacizumab |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b648t-994fe4ef33df52a1cd23f78fa421ecfbb1f0def5a29dd9622101fcf861051f8f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1745-6215-9-56 |
| PMID | 18854025 |
| PQID | 2794925092 |
| PQPubID | 44365 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_117a77921ae34eb8b9abe4b87bac8c7b pubmedcentral_primary_oai_pubmedcentral_nih_gov_2576049 biomedcentral_primary_oai_biomedcentral_com_1745_6215_9_56 proquest_miscellaneous_734189531 proquest_journals_2794925092 gale_infotracmisc_A188000395 gale_infotracacademiconefile_A188000395 pubmed_primary_18854025 crossref_citationtrail_10_1186_1745_6215_9_56 crossref_primary_10_1186_1745_6215_9_56 springer_journals_10_1186_1745_6215_9_56 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-10-14 |
| PublicationDateYYYYMMDD | 2008-10-14 |
| PublicationDate_xml | – month: 10 year: 2008 text: 2008-10-14 day: 14 |
| PublicationDecade | 2000 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2008 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | H Hurwitz (269_CR5) 2004; 350 RL Avery (269_CR6) 2006; 113 PJ Rosenfeld (269_CR8) 2006; 355 DG Pelli (269_CR13) 1998; 2 ES Gragoudas (269_CR4) 2004; 351 KG Csaky (269_CR12) 2008; 49 RA Costa (269_CR10) 2006; 47 JS Mansfield (269_CR14) 1993 R Klein (269_CR1) 1999; 106 RF Spaide (269_CR7) 2006; 26 269_CR11 269_CR15 DS Friedman (269_CR2) 2004; 122 269_CR3 DM Brown (269_CR9) 2006; 355 8298418 - BMJ. 1994 Jan 8;308(6921):81-106 15078675 - Arch Ophthalmol. 2004 Apr;122(4):564-72 10366071 - Ophthalmology. 1999 Jun;106(6):1056-65 15625332 - N Engl J Med. 2004 Dec 30;351(27):2805-16 17003454 - Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78 10532441 - Arch Ophthalmol. 1999 Oct;117(10):1329-45 15175435 - N Engl J Med. 2004 Jun 3;350(23):2335-42 17021318 - N Engl J Med. 2006 Oct 5;355(14):1419-31 16603955 - Retina. 2006 Apr;26(4):383-90 18234989 - Invest Ophthalmol Vis Sci. 2008 Feb;49(2):479-89 17021319 - N Engl J Med. 2006 Oct 5;355(14):1432-44 16458968 - Ophthalmology. 2006 Mar;113(3):363-372.e5 11336929 - Am J Ophthalmol. 2001 May;131(5):541-60 |
| References_xml | – volume: 26 start-page: 383 year: 2006 ident: 269_CR7 publication-title: Retina doi: 10.1097/00006982-200604000-00001 – volume: 2 start-page: 187 year: 1998 ident: 269_CR13 publication-title: Clin Vis Sci – start-page: 232 volume-title: Ophthalmic and Visual Optics/Noninvasive Assessment of the Visual System Technical Digest year: 1993 ident: 269_CR14 – volume: 49 start-page: 479 year: 2008 ident: 269_CR12 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1132 – ident: 269_CR11 doi: 10.1001/archopht.117.10.1329 – volume: 351 start-page: 2805 year: 2004 ident: 269_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa042760 – volume: 47 start-page: 4569 year: 2006 ident: 269_CR10 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.06-0433 – ident: 269_CR15 doi: 10.1136/bmj.308.6921.81 – volume: 113 start-page: 363 year: 2006 ident: 269_CR6 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2005.11.019 – volume: 350 start-page: 2335 year: 2004 ident: 269_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 – ident: 269_CR3 doi: 10.1016/S0002-9394(01)00967-9 – volume: 106 start-page: 1056 year: 1999 ident: 269_CR1 publication-title: Ophthalmology doi: 10.1016/S0161-6420(99)90255-5 – volume: 122 start-page: 564 year: 2004 ident: 269_CR2 publication-title: Arch Ophthalmol doi: 10.1001/archopht.122.7.1019 – volume: 355 start-page: 1419 year: 2006 ident: 269_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 355 start-page: 1432 year: 2006 ident: 269_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa062655 – reference: 17021319 - N Engl J Med. 2006 Oct 5;355(14):1432-44 – reference: 10532441 - Arch Ophthalmol. 1999 Oct;117(10):1329-45 – reference: 15078675 - Arch Ophthalmol. 2004 Apr;122(4):564-72 – reference: 10366071 - Ophthalmology. 1999 Jun;106(6):1056-65 – reference: 17021318 - N Engl J Med. 2006 Oct 5;355(14):1419-31 – reference: 16603955 - Retina. 2006 Apr;26(4):383-90 – reference: 8298418 - BMJ. 1994 Jan 8;308(6921):81-106 – reference: 11336929 - Am J Ophthalmol. 2001 May;131(5):541-60 – reference: 16458968 - Ophthalmology. 2006 Mar;113(3):363-372.e5 – reference: 17003454 - Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78 – reference: 18234989 - Invest Ophthalmol Vis Sci. 2008 Feb;49(2):479-89 – reference: 15175435 - N Engl J Med. 2004 Jun 3;350(23):2335-42 – reference: 15625332 - N Engl J Med. 2004 Dec 30;351(27):2805-16 |
| SSID | ssj0043934 ssj0017864 |
| Score | 1.937412 |
| Snippet | Background
The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal... The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection... BackgroundThe management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal... BACKGROUND: The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal... Abstract Background The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 56 |
| SubjectTerms | Age Biomedicine Clinical trials Drug dosages Drug therapy Funding Health Sciences Hypotheses Macular degeneration Medical personnel Medicine Medicine & Public Health Monoclonal antibodies Patients Recruitment Statistics for Life Sciences Study Protocol Vascular endothelial growth factor Visual acuity |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFDZoDwghIe4UBjoPSAyJaI2bi723DjGtSOOJob1ZdmyzjjaZlrZS-VH8CH4Z5zhJt2wgXpD6kvjEsd1zjc_5zNgbo4VFIZNRxk0Sob3NIpEaG_mYu6HPNXoJVJx89Dk7PE4-naQnV476opywBh64WbjdOM51nkseazdKnBFGauMSI3KjC1HkhrTvUA67YKrRwWhlm_3kPElxFHHawjXGItvd3ItkRMdW9-rcZz3zFFD8b-rqK8bqeiLltd3UYKQOHrD7rXcJ42ZWD9ltVz5id47a_fPHt-6NAW2TrfDPdfY92GppZi6a6_q7s3B-ihYNJpPJ7uQrBNhZqDyggwiOcCZ0sQZ8Fmrt3SI0jVcaFUT56yfs7LuVLqY_lnNt3sGUhrmaUg77DC_OQrZXWUOX7w6LCrpPGNAUgK2RDuqlIdoa6OMwoF6-qKYWuyjdJmG2TT6CmuJ4fH5NfaFKjEJNDnY914EOrPsWALWJeg-6-k8Ih5RgI6WtPGHHBx-_fDiM2vMgIpMlYhFJmXiXOD8aWZ9yHReWj3wuvE547ApvTOyH1vlUc2mtzDhGs7EvvEAPMY298KOnbKusSvecgdOpxB8FdzZBJSeTzGpKIXdaaz7kA7bXYwt13mB_KELj7rfg2iniKUU8paRKswGLOh5SRYu0Tgd-zFSIuER2g_7thr57z98o94kle6MJN1BiVCsx6l8Sg68jhlakwXBYyD5NIQauDGGBqTFB9FHNdjpg2z1KZM6i39yJhGo1X604KniJfrXENYRNMz1J2XzIMMta5eg6CYnaf8CeNQJ0OW8hMIbg2HfeE63elPst5fQ0wKJT6Izx7oDtdEJ4Oao_L-eL_7GcL9ld3mIkx8k221pcLN0rdFQX5nXQSb8BJxuW5g priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxEDZQJISQEG8CBc0BiSJhpevsw-4FpYiqQSoninqz7LXdBtLd0k0qlR_Fj-CXMePspmwLSLkkM-u1nfE87JnPjL2yRjpcZIrnwqYc7W3OZWYdD4nwm6Ew6CVQcfLep3x3P_14kB20G25Nm1bZ6cSoqF1d0h75UKDgKLTXSrw7-c7p1ig6XW2v0LjBbkboMpTn4mAVcCWFzNMWqDGR-RCd7wz7lGRccbqwulfhPusZpojff1VL_2GmLqdQXjpHjeZp5x672_qVMF4Kwn123VcP2K299uT84bU7Y0Cr5Gr8W717C65e2Jnnx6b55h2cHKEtg8lkMpx8gQg4C3UAdA3BE8KEKc8Bn4XGBD-PpPGZQdVQ_foJG9v-zJTTH4tjY9_AlLp5NqXs9Rl--RrzvKoGukx3mNfQbV7AsvTrHPmgWVjibYC2hQE18mk9ddhE5Vepsm3aETQUwePz59QWKkMeq3Gw6WMT-cD5wwilTdxb0FV-QryeBImUsPKI7e98-Px-l7c3QXCbp3LOlUqDT30YjVzIhElKJ0ahkMGkIvFlsDYJm86HzAjlnMoFxrFJKINE3zBLggyjx2ytqiv_lIE3mcIPhXUuRfWm0twZSh73xhixKQZsqycW-mSJ-qEJh7tPwbnTJFOaZEorneUDxjsZ0mWLsU5Xfcx0jLVkfoX_9Yq_e8-_OLdJJHu9iT_Up4e6VTIE3G6KQonE-FHqrbTKWJ9aWVhTyrKw-DoSaE26C7uF4rMswcCZIRQwPSZwPqrWzgZsvceJwln2yd2S0K3Oa_TFCh0wWJHpScrjQ4FZNLpAp0kq1PsD9mS5gC7GLSVGDwLbLnpLqzfkPqWaHkVAdAqaMdIdsI1uEV706u_T-ez_A3jObosW9zhJ19na_HThX6DzObcvo4b5Dboui2Q priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwEDdjSAghIf4NCgPdAxJDIlrz395bh5hWpPFE0d4sO7a3QptMTVtpfCg-BJ-MOzfpSAsSUl9Snx3HufvdXXx3ZuyNVtygkIkgi3QSoL7NAp5qE7gwsn2XK7QSKDn57HN2Oko-nafnO6zf5sL4aPd2S9IjtRdrnh2i6ZziiGEaiCDNbrM7KfrtJIqjaNBiL2rXOGlKM2732chpn3RUka_Yv43LfyimzaDJjZ1Tr5BOHrIHjSUJg9Wrf8R2bPmY3T1r9sqf3Lo_ANRDpsIXac17MNVCT2wwVfV3a-DqErUXDIfDw-FX8CVmoXKAxiBYqimhimvAvlArZ-e-abBUCAblr59wcGyXqhj_WEyVfgdjmuZyTPHqE7z45iO7yhra2HaYV9B-roBVstc10kG90ERbA30IBsTgWTU2OERp18GxTaAR1OSzY_9rGgvhL_D5Nzj0VHk6MPbCF88m6iNocz3BH0iCjRSi8pSNTj5--XAaNGc_BDpL-DwQInE2sS6OjUsjFRYmil3OnUqi0BZO69D1jXWpioQxIovQcw1d4Thag2nouIv32G5ZlfY5A6tSgT9y5EyCgCaSzCgKF7dKKeShHjvqsIW8WtX5kFR5u9uCayeJpyTxlBQyzXosaHlIFk1VdTrcYyK9d8WzLfq3a_r2Pv-iPCaW7MzG_1HNLmQDK1SqXeW5iEJl48RqroXSNtE816rgRa7xdsTQktAKp4Xss0q6wJWhul9yQOX4KD877bH9DiUyZ9FtbkVCNihXywjBXKANLXANYd1MPSlyDxlmUcsczSQuEOl77NlKgG6em3P0FyIcO--IVueRuy3l-NKXQCc3GX3bHjtohfBmVn9fzhf_T_qS3Yuaqsdhss9257OFfYWm51y_9mjzGz8ihkY priority: 102 providerName: Springer Nature |
| Title | A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design |
| URI | https://link.springer.com/article/10.1186/1745-6215-9-56 https://www.ncbi.nlm.nih.gov/pubmed/18854025 https://www.proquest.com/docview/2794925092 https://www.proquest.com/docview/734189531 http://dx.doi.org/10.1186/1745-6215-9-56 https://pubmed.ncbi.nlm.nih.gov/PMC2576049 https://doaj.org/article/117a77921ae34eb8b9abe4b87bac8c7b |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR39axMxNLoNRBDx2-os-UFwA8_t0vtIBiK3sbEONmRa2W8huSRbtbubvXZY_3rfS-86b5sIpaX3XnK53PtM3nsh5K1W3ACTiSBhOgpA3yYBj7UJXMjspksVWAmYnHx4lOwPooOT-OQq_qmewOpW1w7PkxqMRx9-_Zx9Aob_6BmeJxtgVMdwrzAORBAnS2QFtFKCjthhtNhRAL0732FucOsCjjfbX8t8H7UUlq_rf1N6_6W-rodWXttf9Wpr7xF5WNubNJsTyGNy1xZPyL3Dekf96Z0HGQVtZUp43da8p6ac6pENzlX1wxp6cQY6jvb7_Y3-N-oL0dLSUTAZqcXKEyqfUWhLK-XsxIOySwUio1g7Xqdr2_ZS5cPf03Ol1-kQx3k5xLD2Efz57gPAioo2IfB0UtJmVYPOc8JmgEerqUbciuJ6MYW3NS6HBroo7CKGto5HohW69tB-hn2BlAx8mg50fa48HjX21NfYRuwt2qSEUn9uCQAxkuUZGeztft3ZD-ojIgKdRHwSCBE5G1nX6xkXMxXmhvVcyp2KWGhzp3XoNo11sWLCGJEwcHBDlzsORmMcOu56z8lyURb2JaFWxQI-6O-ZCOSeiBKjMKrcKqXYJuuQrRZdyIt5ORCJBbrbEJg7iUQlkaikkHHSIUFDRDKvi6_jGSAj6Z0wntzAf7fAb-7zL8xtpMnWaPyFcnwqa-mDFd1VmgoWKtuLrOZaKG0jzVOtcp6nGm6HFC2RzWBYQD_z3AyYGSwPJjOs2odp3HGHrLYwgTrzNrjhCdnwsmQg8wWY2gLmkC7A2BID_IBgppVMwZriAhRCh7yYc9DVc3MObgWDvtMWb7UeuQ0phme-Ujp60-ACd8haw4VXo7p9Ol_9f4SvyX1WF0UOo1WyPBlP7RuwTCe6S5bSk7RLVrLs4MsB_G7vHn0-hqs7yU7Xr_Z0vVCC7wHL_gCq1pcy |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFDZjkwAhIe4UBpwHECARbXFzsSch1MGmlV2E0Ib2ZuzY3gpdM5Z2qPyo_Qh-GeekSUc24G1SX1qfOLb7-Vzsc2HsmdHC4iaTQcJNFKC8TQIRGxv4kLtFn2rUEig4eXMrWduJPuzGuzPspI6FIbfKmieWjNrmGZ2RL3AEjkR5Lfnbw-8BVY2i29W6hMYEFutu_ANNtuJN9z3-v885X13ZfrcWVFUFApNEYhhIGXkXOd9uWx9zHWaWt30qvI546DJvTOgXrfOx5tJamXC0iUKfeYF6Rhx64dvY72U2F1FE6yybW17Z-vhpem-RiiSqUkOGIllAdT_GVQjjQAZUIrsRU99viMKyYsB5ufCHYDzrtHnm5rYUiKs32Y1Kk4XOBHq32Iwb3GZXNqu7-juXrncA5aDNEUjOvgabj0zfBQe6-OYsHO6j9IRut7vQ_QxlilvIPaAyCo5yWuhsDPgsFNq7YdnUOdbIjAa_TuDlsjvWWe_n6ECbV9CjYR73yF--j1--lp5lgwJq33oY5lAfl8Ak2GyMdFCMDNEWQAfRgDLgKO9Z7GLgps65laMTFHRmgM-PqS9kv0EZ_4NdH-iSDqzbK5N3E_US1LGmUBZEwUZykbnLdi4EJffY7CAfuAcMnI4lfsiQtBEyVBklVpO7utNa80XeYksNWKjDSZ4RRZm_my24doowpQhTSqo4abGgxpDKqqzuVFykr0rrTiTn6F9M6ev3_ItymSDZGE35Q360pyq2RqnidZpKHmrXjpwRRmrjIiNSozORpQZfR4BWxC1xWAifSdAHrgzlHVMdSgdI8eFxi803KBGcWbO53hKq4rKFOuUJLQbTZnqSPAcRMKNCpaimCYmSpsXuTzbQ6byFQHuFY99pY2s1ptxsGfT2yxTsZKajbd1iL-tNeDqqvy_nw_9P4Cm7ura9uaE2ulvrj9g1XmVdDqN5Njs8GrnHqPoOzZOK3wD7ctEs7jeJactl |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFDZjSBNCQtwpDPADiCERdXFzsSch1DGmlbGJBzbtzdixvRXapCztUPlR_AAe-WWc4yYd2YC3SX1pfeLY7udzsc-FkKdacQObTAQJ01EA8jYJeKxN4EJmV12qQEvA4OSd3WRrL3p3EB8skJ91LAy6VdY80TNqU2R4Rt5mABwB8lqwtqvcIj5sbL4efQ2wghTetNblNGYQ2bbTb2C-la96G_BfP2Ns8-3HN1tBVWEg0EnEx4EQkbORdZ2OcTFTYWZYx6XcqYiFNnNah27VWBcrJowRCQP7KHSZ46BzxKHjrgP9XiZX0g5oVbCX0oO5sRemPImqJJEhT9qg-MewHmEciACLZTei6wcNoehrB5yXEH-IyLPum2fucL1o3LxBrlc6Le3OQHiTLNj8FlnaqW7tb1-61qUgEU0BkLLmJTXFRA9sMFTlF2vo6AjkKO31eu3ePvXJbmnhKKil1GJ2C5VNKTxLS-Xs2Dd1TxSwpfzXD7qybk9U1v8-GSr9gvZxmCd99JwfwJfP3scsL2ntZU_HBa0PTugs7GwKdLScaKQtKR5JU5AGx0XfQBe5nbvpVi5PtMTTA3h-in0BIw58JBB0PVSejhp76NN4I_UaraNOqS-NAo3oLHOH7F0IRu6SxbzI7X1CrYoFfNCkNBGwVhElRqHjulVKsVXWImsNWMjRLOOIxBzgzRZYO4mYkogpKWSctEhQY0hmVX53LDMykN7O48k5-udz-vo9_6JcR0g2RuN_KI4PZcXgMGm8SlPBQmU7kdVcC6VtpHmqVcazVMPrENAS-SYMC-AzC_-AlcEMZLKLiQExUjxukeUGJYAzazbXW0JW_LaUp9yhRei8GZ9EH0IAzKSUKShsXIDMaZF7sw10Om_OwXJh0Hfa2FqNKTdb8v6RT8aOBjtY2S2yUm_C01H9fTkf_H8CT8gSMDb5vre7_ZBcZVX65TBaJovj44l9BDrwWD_2zIaSTxfN3X4D9NXOLA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomised%2C+double-masked+phase+III%2FIV+study+of+the+efficacy+and+safety+of+Avastin%28R%29+%28Bevacizumab%29+intravitreal+injections+compared+to+standard+therapy+in+subjects+with+choroidal+neovascularisation+secondary+to+age-related+macular+degeneration%3A+clinical+trial+design&rft.jtitle=Trials&rft.au=Patel%2C+Praveen+J&rft.au=Bunce%2C+Catey&rft.au=Tufail%2C+Adnan&rft.date=2008-10-14&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=9&rft.spage=56&rft_id=info:doi/10.1186%2F1745-6215-9-56&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |